Network meeting at Thorbjørnrud Exciting reaserch results, new possibility for collaboration, and a grate visit to Hadeland glassverk.
Signalling pathways identified in chemoresistant tumor models open new treatment possibilities for a group of patients with triple negative breast cancer
ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
SATT: Secondary Adjuvant (rescue) Treatment with docetaxel (Taxotere) and detection of isolated tumor cells in bone marrow as a surrogate marker for effect in node positive and high risk node negative breast cancer after standard
